0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HGF R

HGF R

Brief Information

Name:Hepatocyte growth factor receptor
Target Synonym:EC 2.7.10,EC:2.7.10.1,HGF receptor,HGF/SF receptor,Hepatocyte growth factor receptor,Tyrosine-protein kinase Met,MET,SF receptor,Scatter factor receptor,MET Proto-Oncogene, Receptor Tyrosine Kinase,Proto-Oncogene C-Met,Met Proto-Oncogene,EC 2.7.10.1,DFNB9
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:46
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

MET-H5256-ELISA
Human HGF R, Fc TagHuman HGF R, Fc Tag (Cat. No. MET-H5256) ELISA bioactivity

Immobilized Human HGF, His Tag (Cat. No. HGF-H52H3) at 2 μg/mL (100 μL/well) can bind Human HGF R, Fc Tag (Cat. No. MET-H5256) with a linear range of 0.6-20 ng/mL (QC tested).

MET-H82E1-MALS-HPLC
Biotinylated Human HGF R, Avitag,His Tag (Cat. No. ) MALS images

The purity of Biotinylated Human HGF R, Avitag,His Tag (Cat. No. MET-H82E1) was more than 90% and the molecular weight of this protein is around 125-145 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human HGF R, Avitag,His TagBiotinylated Human HGF R, Avitag,His Tag (Cat. No. MET-H82E1) ELISA bioactivity

Immobilized Human HGF, His Tag (Cat. No. HGF-H52H3) at 2 μg/mL (100 μL/well) can bind Biotinylated Human HGF R, Avitag,His Tag (Cat. No. MET-H82E1) with a linear range of 0.039-0.313 μg/mL (QC tested).

Synonym Name

MET,AUTS9,HGFR,RCCP2,c-Met

Background

The SARS-CoV-2 Spike S2-coupled Magnetic Beads is produced by coupling biotinylated SARS-CoV-2 spike S2 protein to streptavidin-conjugated magnetic beads. Because Streptavidin (SA) has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the SA beads irreversibly. The pre-coupled beads are ready to use for capturing anti-SARS-CoV-2 antibody or ACE2 protein from your sample with high specificity.

Clinical and Translational Updates

Related Molecule

HGF

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Crizotinib PF-1066; PF-2341066; PF-02341066; PF-002341066 Approved Pfizer Pharmaceuticals Ltd (China) 赛可瑞, Xalkori United States Lymphoma, Large-Cell, Anaplastic Pf Prism Cv 2011-08-26 Kidney Diseases; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung Details
Tepotinib hydrochloride hydrate EMD-1214063; MSC-2156119; MSC-2156119J Approved Merck Serono テプミトコ, TEPMETKO, Tepmetko United States Carcinoma, Non-Small-Cell Lung Emd Serono Inc 2020-03-25 Solid tumours; Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Savolitinib HM-5016504; AZD-6094; HMP-504; HMPL-504 Approved Hutchison Medipharma Ltd Mainland China Carcinoma, Non-Small-Cell Lung Hutchison Medipharma Ltd 2021-06-22 Kidney Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Kidney Diseases; Neoplasms; Urologic Neoplasms; Carcinosarcoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Capmatinib Hydrochloride NVP-INC280-NX; INCB-28060; C2A374O70X; INC-280; INCB-028060 Approved Incyte Corp, Novartis Pharma Ag Tabrecta Japan Carcinoma, Non-Small-Cell Lung Novartis Pharma Ag 2020-05-06 Liver Neoplasms; Solid tumours; Carcinoma; Adenocarcinoma of Lung; Triple Negative Breast Neoplasms; Hepatic Insufficiency; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
Amivantamab JNJ-372; JNJ-61186372 Approved Genmab, Janssen Global Services Llc RYBREVANT United States Carcinoma, Non-Small-Cell Lung Janssen Biotech Inc 2021-05-21 Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Cabozantinib S-malate BMS-907351; XL-184 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Solid tumours; Pain; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SAIT-301 SAIT-301 Phase 1 Clinical Samung Medical Centre Neoplasms Details
Emibetuzumab LA-480; LY-2875358 Phase 2 Clinical Eli Lilly And Company Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Lymphoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No.4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms Details
Boxitinib Hydrochloride Phase 1 Clinical Hec Pharm Co Ltd Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms Details
Alirinetide GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 Phase 2 Clinical Genervon Biopharmaceuticals Llc Stroke; Parkinson Disease; Amyotrophic Lateral Sclerosis Details
CM-118 CM-118 Phase 1 Clinical Xcovery Carcinoma, Non-Small-Cell Lung Details
ABN-401 ABN-401; KDDF-201603-08 Phase 2 Clinical Abion Inc Neoplasms Details
Sym-015 Sym-015 Phase 2 Clinical Symphogen Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CBT-101 CBT-101 Phase 1 Clinical Crown Bioscience Neoplasms Details
TPX-0022 TPX-0022 Phase 1 Clinical Turning Point Therapeutics Neoplasms Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Phase 2 Clinical Mirati Therapeutics Carcinoma, Non-Small-Cell Lung Details
JNJ-38877618 OMO-1; JNJ-38877618 Phase 2 Clinical Johnson & Johnson Neoplasms Details
Anti-cMet SIMPLE Antibody ARGX-111 Phase 1 Clinical Argen-X Neoplasms Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) Phase 1 Clinical The Second Hospital Of Nanjing Medical University Carcinoma, Hepatocellular Details
SAR-125844 SAR-125844 Phase 2 Clinical Sanofi Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ASLAN-002 ASLAN-002; BMS-777607; BMS-797669 Phase 2 Clinical Bristol-Myers Squibb Company Stomach Neoplasms; Neoplasms; Breast Neoplasms Details
RXDX-106 RXDX-106 Phase 1 Clinical Teva, Daiichi Sankyo Co Ltd Solid tumours; Neoplasms Details
AMG-337 AMG-337 Phase 2 Clinical Amgen Inc Solid tumours; Stomach Neoplasms; Sarcoma, Clear Cell; Esophageal adenocarcinoma Details
GST-HG161 GST-HG161 Phase 1 Clinical Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd Solid tumours; Carcinoma, Hepatocellular Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
SPH3348 SPH-3348 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Solid tumours Details
HS-10241 HS-10241 Phase 1 Clinical Jiangsu Hansoh Pharmaceutical Group Co Ltd Liver Neoplasms; Solid tumours; Carcinoma; Stomach Neoplasms; Lung Neoplasms Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Liver Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant plasmid-hepatocyte growth factor Pudk-HGF Phase 3 Clinical Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd, Academy Of Military Medical Sciences Ischemia; Peripheral Arterial Disease Details
BPI-9016 BPI-9016; BPI-9016M Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Esa Biotech Solid tumours; Esophageal Neoplasms; Prostatic Neoplasms Details
SHR-A1403 SHR-A1403 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details
Glumetinib SCC244; HH-SCC244 Phase 2 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Greenvalley Pharmaceutical Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Solid tumours; Biliary Tract Neoplasms; Skin Melanoma; Pancreatic Neoplasms; Microsatellite instability-high cancer; Cholangiocarcinoma; Breast Neoplasms; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Gallbladder Neoplasms; Lymphoma, Non-Hodgkin; Neoplasm Metastasis Details
EMB-01 EMB-01 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
XL-092 XL-092 Phase 1 Clinical Exelixis Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms Details
S-49076 S-49076 Phase 2 Clinical Servier Glioblastoma; Carcinoma, Non-Small-Cell Lung Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Phase 1 Clinical Deciphera Solid tumours; Neoplasms Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Stomach Neoplasms Details
TAS-115 TAS-115 Phase 1 Clinical Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd Neoplasms Details
Telisotuzumab vedotin ABT-399; ABBV-399 Phase 3 Clinical Abbvie Inc Solid tumours; Carcinoma, Non-Small-Cell Lung Details
RC-108 RC-108; RC108 Phase 1 Clinical Rc Biotechnologies Ltd Solid tumours Details
Refanalin BB-3; SNV-003; ANG-3777 Phase 3 Clinical Angion Biomedica Myocardial Infarction; Pneumonia; Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Acute Kidney Injury Details
Bozitinib APL-101; CBT-101; CBI-3103; PLB-1001 Phase 2 Clinical Beijing Purunao Biotechnology Co Ltd, Cbt, Heng Kang, Crown Bioscience Kidney Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Glioblastoma; Ganglioglioma; Brain Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular Details
Ningetinib Tosylate CT-053; CT-053-PTSA Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Sitravatinib MG-516; MG-91516; MGCD-516; IND-155305 Phase 3 Clinical Mirati Therapeutics Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular Details
MCLA-129 MCLA-129 Phase 2 Clinical Merus Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AL-2846 AL-2846 Phase 2 Clinical Advenchen Laboratories Nanjing Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Bone metastases; Liver Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neurofibroma; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1 Details

This web search service is supported by Google Inc.

totop